Bone sarcomas: pathogenesis and new therapeutic approaches, IBMS BoneKEy, vol.8, issue.9, pp.402-414, 2011. ,
DOI : 10.1138/20110531
Osteosarcoma (osteogenic sarcoma), Orphanet J. Rare Dis, vol.26, 2007. ,
Current Therapeutic Strategies and Novel Approaches in Osteosarcoma, Cancers, vol.2012, issue.2, pp.591-616, 2013. ,
DOI : 10.1155/2012/523432
URL : https://doi.org/10.3390/cancers5020591
Chemotherapy,en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma, Cancer, vol.32, issue.1, pp.1-11, 1976. ,
DOI : 10.1002/1097-0142(197601)37:1<1::AID-CNCR2820370102>3.0.CO;2-3
Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study, Clin. Orthop, vol.270, pp.8-14, 1991. ,
Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group., Journal of Clinical Oncology, vol.15, issue.1, pp.76-84, 1997. ,
DOI : 10.1200/JCO.1997.15.1.76
Genomic and proteomic profiling of osteosarcoma Bone Cancer: progression and therapeutic approaches, pp.181-192, 2010. ,
DOI : 10.1016/b978-0-12-374895-9.00015-3
URL : http://doi.org/10.1016/b978-0-12-374895-9.00015-3
Targeted therapies for bone sarcomas, BoneKEy Reports, vol.2 ,
DOI : 10.1038/bonekey.2013.112
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817966/pdf
mTOR Inhibitors (Rapamycin and its Derivatives) and Nitrogen Containing Bisphosphonates: Bi-Functional Compounds for the Treatment of Bone Tumours, Current Medicinal Chemistry, vol.14, issue.13, pp.1381-1387, 2007. ,
DOI : 10.2174/092986707780831159
The emerging mechanisms of isoform-specific PI3K signalling, Nature Reviews Molecular Cell Biology, vol.11, issue.5, pp.329-341, 2010. ,
DOI : 10.1128/MCB.10.12.6742
Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases, Science Signaling, vol.2, issue.195, 2011. ,
DOI : 10.1126/science.1208071
<i>PIK3CA</i> Mutations in Advanced Cancers: Characteristics and Outcomes, PIK3CA mutations in advanced cancers: characteristics and outcomes, pp.1566-1575, 2012. ,
DOI : 10.18632/oncotarget.716
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681495/pdf
Identification and characterization of NVP- BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity, Mol. Cancer Ther, vol.7, pp.1851-1863, 2008. ,
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma, Clin. Cancer Res, vol.17, pp.2373-2384, 2011. ,
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition, Proc. Natl ,
DOI : 10.1016/j.bcp.2006.08.009
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas, Blood, vol.115, issue.22, pp.4455-4463, 2010. ,
DOI : 10.1182/blood-2009-10-251082
NVP-BEZ235 as a New Therapeutic Option for Sarcomas, Clinical Cancer Research, vol.16, issue.2, pp.530-540, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-0816
High metastatic efficiency of human sarcoma cells in Rag2/gc double knockout mice provides a powerful test system for antimetastatic targeted therapy ,
Jasmin, Studies of bone and soft-tissue tumours induced in rats with radioactive cerium chloride ,
Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation, Cancer Letters, vol.188, issue.1-2, pp.213-219, 2002. ,
DOI : 10.1016/S0304-3835(02)00433-0
Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma, In Vivo, vol.16, pp.223-228, 2002. ,
Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption, Cancer Res, vol.67, pp.7308-7318, 2007. ,
Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy, Clinical Cancer Research, vol.19, issue.14, pp.3796-3807, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-3647
The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets, Sarcoma, p.932451, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00667904
TOR Signaling in Growth and Metabolism, Cell, vol.124, issue.3, pp.471-484, 2006. ,
DOI : 10.1016/j.cell.2006.01.016
URL : https://doi.org/10.1016/j.cell.2006.01.016
Alteration of Cellular Behavior and Response to PI3K Pathway Inhibition by Culture in 3D Collagen Gels, PLoS ONE, vol.7, issue.10, p.48024 ,
DOI : 10.1371/journal.pone.0048024.g011
MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma, PLoS One, vol.8, p.53906, 2013. ,
Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K???Akt signaling, Archives of Biochemistry and Biophysics, vol.526, issue.1, pp.52638-52681, 2012. ,
DOI : 10.1016/j.abb.2012.07.003
Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920- induced blockade of the Ras ,
A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8, Oncology Reports, pp.14-847, 2005. ,
DOI : 10.3892/or.14.4.847
Correlation between Ki67 and Breast Cancer Prognosis, Oncology, vol.57, issue.4, pp.219-225, 2013. ,
DOI : 10.1016/j.ejso.2007.11.009
Ki-67, marker of proliferation, Ann. Pathol, vol.17, pp.25-30, 1997. ,
CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis, Blood, vol.120, issue.11, pp.2330-2339, 2012. ,
DOI : 10.1182/blood-2012-01-406108
Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging, Cancer Research, vol.68, issue.16, pp.6598-6607, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-1044
Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus, Critical Reviews in Oncology/Hematology, vol.87, issue.2, pp.101-111, 2013. ,
DOI : 10.1016/j.critrevonc.2013.05.015
NVP-235, a dual pan class I PI3K and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells, J. Bone Miner. Res, pp.25-2126, 2010. ,
Skeletal overexpression of noggin results in osteopenia and reduced bone formation, Endocrinology, vol.144, pp.1972-1978, 2003. ,
Conditional Inactivation of Noggin in the Postnatal Skeleton Causes Osteopenia, Endocrinology, vol.153, issue.4, pp.1616-1626, 2012. ,
DOI : 10.1210/en.2011-1604